European Prostate Cancer Virtual Support Group, March 18, 2026

European Prostate Cancer Virtual Support Group, March 18, 2026

by | Mar 19, 2026 | Active Surveillance PCa, High Risk/Recurrent/Advanced Prostate Cancer, Low/Intermediate Prostate Cancer, Prostate Cancer, Recorded Groups, Uncategorized

European Prostate Cancer Virtual Support Group, March 18, 2026

Our European AnCan audience, who find it tough to attend meetings at late hours of the night, have requested a meeting at a more time-friendly hour. Unlike our other prostate groups, this meeting is open to all levels until there is a quorum to establish separate groups for different levels of prostate cancer. The meeting will start with the lowest grade, allowing men to drop out along the way.

This peer-led, free, and drop-in meeting is open to patients and care partners and will be conducted in English. It is open to all; however, Euro-based participants are given priority. This group is held on the 3rd Wednesday of each month at 2 pm Eastern/ 8 pm CET in The Barniskis Room (222-583-973) https://ancan.org/barniskis Sign up to receive a Reminder at https://ancan.org/contact-us

AnCan thanks the following sponsors for making this recording possible: Novartis, Telix, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.

AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.

AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download

All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/

Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room

Listen to our recent Estradiol discussion https://ancan.org/learn-from-ancans-emperors-of-estradiol-021626/

Recent article on AnCan in Rarity life. https://ancan.org/rarity-life-magazine-featuring-rick-davis/

Hear Founder, rick davis talk about how AnCan came to be in this 20-min podcast dropped this week on Empowered Patient Radio http://empoweredpatientradio.com/virtual-support-groups-remove-barriers-encourage-sharing-honest-experiences-to-fight-misinformation-with-rick-davis-ancan

Editor’s Pick: Is 5 years on enzalutamide without a change too long?

 

Topics Discussed

Recurrence well handled by a trial immunotherapy in Germany… or was it the radiation therapy; HT French style gives little wiggle room; surgery coming up fast at Martini to address advanced diagnosis; HT is working for Brit – BUT does it need changing up?; hyperbaric treatment in Eire to address RT cystitis

Chat

Low/Intermediate PCa Video Chat, March 9, 2026

Low/Intermediate PCa Video Chat, March 9, 2026

by | Mar 11, 2026 | Cancer Caregivers, Cancer Resources, Low/Intermediate Prostate Cancer, Recorded Groups

Low/Intermediate PCa Video Chat, March 9, 2026

Low/Intermediate PCa Video Chat, March 9, 2026

AnCan is grateful to the following sponsors for making this recording possible: Novartis, Telix, Blue Earth Diagnostics, and Foundation Medicine.

WELCOME all to our newly recorded Low/Intermediate Prostate Cancer Group. To receive notice when new recordings are posted, either follow us on this YouTube Channel or sign up to our Blog via https://ancan.org/contact-us/ – check New Blog box.

Join our other free and drop in groups:
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime!

Editor’s Pick: The value of connecting with other AnCan peers to compare doctor recommendations and treatment experiences. (bj)

Topics Discussed
Management of Benign Prostatic Hyperplasia (BPH) and prostate size; comparison of radiation modalities such as stereotactic body radiation therapy (SBRT), intensity-modulated radiation therapy (IMRT), magnetic resonance-guided linear accelerator (MRI-Linac) and brachytherapy; comparison of androgen deprivation therapy (ADT) medications: Orgovyx vs Lupron; importance of genomic tests like Decipher, Prolaris, Artera AI, and the PROMISE study (germline testing); discussion on surgical options and surgeon recommendations;  advantages of transperineal over transrectal biopsies; benefits of MRI-fusion biopsies for targeted sampling; veterans get medical treatments through Veterans Affairs (VA) can use Community Care to get access to specialized medical care outside the VA; lymph node involvement seen in a PSMA scan changes disease categorization and requires more advanced drugs; importance of consulting a cardio-oncologist when adding ADT treatments for prostate cancer while recovering from heart surgery; discussion between how long a low/intermediate prostate cancer patient can wait between a diagnosis requiring an active treatment (such as prostatectomy, radiation, hormone therapy) and starting active treatment;  the value of connecting with other AnCan peers at similar stages of their journey to compare doctor recommendations and treatment experiences.

Chat

Stuart sent a chat · 8:01 PM
Dr. Ming Zhou Mount Sinai Health System Department of Pathology, Box 1194 Annenberg Bldg. 15th FL 1468 Madison Ave New York, NY 10029 Email: Ming.zhou@mountsinai.org Telephone: (212)241-8881

Stuart sent a chat · 8:02 PM
Dr. Jonathan Epstein – https://advanceduropathology.com/  Tel:516-760-2037    jepstein@imppllc.com

Bob in Georgia sent a chat · 8:34 PM
can you put those doctor name and contacts in the chat?

AnCan – Rick sent a chat · 8:40 PM
Eggener https://www.uclahealth.org/providers/scott-eggener

AnCan – Rick sent a chat · 8:41 PM
Kishan  UCLA  https://www.uclahealth.org/providers/amar-kishan

AnCan – Rick sent a chat · 8:41 PM
Eggener is UCLA

David in Portland, OR sent a chat · 8:43 PM
Paper on delaying treatment (Mack Roach is co-author): “Delayed Definitive Management of Localized Prostate Cancer: What Do We Know?” Prostate Cancer and Prostate Diseases, Aug. 2024, https://www.nature.com/articles/s41391-024-00876-2

Larry S – ADT by estradiol sent a chat · 8:46 PM
Get baselines for lyour 1) Bone density 2) Hormone levels (especially testosterone) 3) your muscle strength and lean to fat ratio.  These can change with ADT and (in my opinion) you want keep track.

AnCan – Rick sent a chat · 8:48 PM
Brisbane – surgeon  UCLA https://www.uclahealth.org/providers/wayne-brisbane

AnCan – Rick sent a chat · 8:49 PM
Peter Carroll – surgeon UCSF  https://urology.ucsf.edu/people/peter-r-carroll

AnCan – Rick sent a chat · 8:50 PM
Matt Cooperberg  surgeon UCSF  https://urology.ucsf.edu/people/cooperberg

AnCan – Rick sent a chat · 8:50 PM
Mack Roach rad onc UCSF  https://www.ucsfhealth.org/mack.roach

Larry S – ADT by estradiol sent a chat · 8:53 PM
Talk to your doctors about the side effects of ADT, especially if you will be using it for very long.

AnCan – Rick sent a chat · 9:11 PM
Bob…  MRLinac at MSKCC Dr. Nagar

Mark WV sent a chat · 9:27 PM
good night

AnCan – Boykin sent a chat · 9:28 PM
good night

Steve in Malaysia sent a chat · 9:32 PM
Was wondering if I can ask a question or 2.

AnCan – Boykin sent a chat · 9:32 PM
Steve I have you on the list…you’re last

Steve in Malaysia sent a chat · 9:32 PM
Thanks 🙂

Steve K sent a chat · 10:01 PM
Good night. Thanks everyone.

AnCan – Boykin sent a chat · 10:01 PM
Good night Steve K

Larry S – ADT by estradiol sent a chat · 10:03 PM
Cannot stay.  Good night.

AnCan – Boykin sent a chat · 10:03 PM
Good night Larry S

AnCan – Rick sent a chat · 10:06 PM
SBRT vs HDR https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2845485?utm_source=email&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=022826

Low/Intermediate PCa Video Chat, March 9, 2026

Low/Intermediate PCa Video Chat, February 23, 2026

by | Mar 5, 2026 | Cancer Caregivers, Cancer Resources, Low/Intermediate Prostate Cancer, Recorded Groups

Low/Intermediate PCa Video Chat, February 23, 2026

Low/Intermediate PCa Video Chat, February 23, 2026

AnCan is grateful to the following sponsors for making this recording possible: Novartis, Telix, Blue Earth Diagnostics, and Foundation Medicine.

WELCOME all to our newly recorded Low/Intermediate Prostate Cancer Group. To receive notice when new recordings are posted, either follow us on this YouTube Channel or sign up to our Blog via https://ancan.org/contact-us/ – check New Blog box.

Join our other free and drop in groups:
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime!

Editor’s Pick: Addressing the unusual: Low PSA with high-grade prostate cancer. (bj)

Topics Discussed
Importance of getting a second reading/opinion on your prostate cancer biopsy results; addressing the unusual: low PSA with high-grade prostate cancer; identifying risk factors that can push you from intermediate-risk to high risk prostate cancer; understanding how gentic testing help determine the best treatment options, espcially when family history exists; evaluating high-dose rate (HDR) brachytherapy as a primary treatment or boost to radiation; comparing transperineal and transrectal biopsies with a focus on lower risk infection and better patient experiences; determining when a patient should move from active surveillence (AS) based on rising PSA or new biospy results.

Chat

AnCan – Stuart sent a chat · 7:58 PM
Dr. Ming Zhou Mount Sinai Health System Department of Pathology, Box 1194 Annenberg Bldg. 15th FL 1468 Madison Ave New York, NY 10029 Email: Ming.zhou@mountsinai.org Telephone: (212)241-8881

AnCan – Stuart sent a chat · 7:59 PM
Dr. Jonathan Epstein – https://advanceduropathology.com/  Tel:516-760-2037    jepstein@imppllc.com

AnCan – Rick sent a chat · 8:04 PM
AnCan’s GU ASCO Poster released today   https://ancan.org/ancan-gu-asco26-survivorship-poster/

Norman Davis sent a chat · 8:13 PM
No. I’ve joined before but I havent joined in a while. I’m just listening tonight

Norman Davis sent a chat · 8:19 PM
Question is this  a call I should be on. I did have treatment 3 yrs ago

Norman Davis sent a chat · 8:20 PM
ok thanks

AnCan – Boykin sent a chat · 8:23 PM
@Norman Davis – I would stay and listen in. It doesn’t hurt and you are already here.

Norman Davis sent a chat · 8:23 PM
Gotcha. I  dont have a reoccurrence

Bill Franklin sent a chat · 8:31 PM
bfranklin@ancan.org

AnCan – Rick sent a chat · 8:49 PM
2nd Opinions for MRIs  Botimage AI for MRIs: https://botimageai.com/prostatid/ ~$250, can also be used for biopsy targeting guidance  NIH 2nd Opinion MRI (no fees): Choyke, Peter (NIH/NCI) Radiologist pchoyke@mail.nih.gov  Second opinion of MRI from Johns Hopkins Images and Reports for Providers | Johns Hopkins Radiology (hopkinsmedicine.org) Email: eradiologycenter@jhmi.edu Phone: 443-287-7378 Fax: 443-769-1210  -Accolade Radiology NY, PA https://accoladeradiology.com/mritap.html  Radiology Check (Switzerland) https://radiologycheck.com/en

AnCan – Rick sent a chat · 8:51 PM
Bx 2nd Opinions       Ep-stine! Dr. Jonathan Epstein – https://advanceduropathology.com/ Tel: 516-760-2037 jepstein@imppllc.com

AnCan – Rick sent a chat · 8:52 PM
Dr. Ming Zhou Mount Sinai Health System Department of Pathology, Box 1194 Annenberg Bldg. 15th FL 1468 Madison Ave New York, NY 10029 Email: Ming.zhou@mountsinai.org Telephone: (212)241-8881

Steve in Malaysia sent a chat · 8:58 PM
I need to head out at 10ish (5 minutes). I’ll followup with Rick and Stuart re: how to think about negotiating costs … I was quoted $100k for HDR and $180k for MR Linac.

Steve in Malaysia sent a chat · 9:01 PM
Also wanted to thank you guys (Rick, Stuart and company) on all your help on this crazy journey… could never had ended up where I did without your help 🙂

AnCan – Rick sent a chat · 9:04 PM
You need to make sure it registers with the Lead Mod.

Clyde sent a chat · 9:07 PM
Hey gang.  Gotta run.  I am graduating to the high risk group, so I will see some of you there.

AnCan – Boykin sent a chat · 9:08 PM
@clyde – Good luck. We will miss you in low/intermediate.

Bob Richards sent a chat · 9:09 PM
I would like to update the group tonight on my situation if possible

Norman Davis sent a chat · 9:21 PM
Good questions. I’ll rejoin next week. Thanks

AnCan – Boykin sent a chat · 9:23 PM
Good night Norman!

AnCan – Boykin sent a chat · 9:26 PM
Nice dog George!

David in Portland, OR sent a chat · 9:40 PM
Prostate Cancer Free Foundation Intermediate Risk graph: https://www.prostatecancerfree.org/compare-prostate-cancer-treatments-intermediate-risk/  High Risk graph: https://www.prostatecancerfree.org/compare-prostate-cancer-treatments-high-risk/

David in Portland, OR sent a chat · 9:41 PM
Prostate Cancer Free Foundation Low Risk graph: https://www.prostatecancerfree.org/compare-prostate-cancer-treatments-low-risk/

George in NC sent a chat · 10:04 PM
Thank you all and good night!  See you in 2 weeks!   Very grateful to AnCan especailly Rick and Stuart!

Larry (Alaska Vet) sent a chat · 10:05 PM
David, can you put a link to that 2024 study also, please?

Bill Franklin sent a chat · 10:05 PM
Good night George.

AnCan – Boykin sent a chat · 10:05 PM
Good night George

Steve in Malaysia sent a chat · 10:06 PM
back

David in Portland, OR sent a chat · 10:18 PM
Albert Chang & Peter Rossi brachytherapy video lecture: https://www.youtube.com/watch?v=QkfB5kkOsm4

[Waiting for name] sent a chat · 10:21 PM
Hi Leon here, trying to get back wit ya. Hit the wrong button

David in Portland, OR sent a chat · 10:22 PM
A Randomized Trial Comparing Quality of Life after Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost with Pelvic External Beam Radiation (Crook, Juanita), 2024: https://www.redjournal.org/article/S0360-3016(24)00381-X/fulltext

David in Portland, OR sent a chat · 10:23 PM
A Randomized Comparison of High-Dose-Rate and Low-Dose Rate Prostate Brachytherapy Combined with External Beam Radiation Therapy for Unfavorable Prostate Cancer: Efficacy Results After Median Follow-Up of 74 Months (Crook, Juanita), 2025: https://www.redjournal.org/article/S0360-3016(25)00303-7/abstract

David in Portland, OR sent a chat · 10:24 PM
HDR Brachytherapy Combined with External Beam Radiotherapy for Unfavorable Localized Prostate Cancer: A Single Center Experience from Inception to Standard of Care (Crook, Juanita), 2025: https://www.brachyjournal.com/article/S1538-4721(25)00004-2/fulltext

Rarity Life Magazine Featuring Rick Davis

Rarity Life Magazine Featuring Rick Davis

by | Feb 27, 2026 | Advocacy, Blood Cancers, Brain Tumors, Cancer Caregivers, Cancer Resources, Exercise, Health Resources, High Risk/Recurrent/Advanced Prostate Cancer, Low/Intermediate Prostate Cancer, mCRPC, Men 'Speaking Freely', Men's Breast Cancer, Mental Health, mHSPC, Multiple Sclerosis, Pancreatic Cancer, Prostate Cancer, Recent News, RMC, Sarcoidosis, Veterans

Rarity Life Magazine Feature: Rick Davis

AnCan’s ambitious CEO and Founder, Rick Davis, recently sat down with Rarity Life, the magazine published by Same But Different Creative, to share the deeply personal journey that led to the creation of AnCan.

In the interview, Rick reflects on his early days navigating a prostate cancer diagnosis — a moment that reshaped his life & his understanding of what true support should look like. Like so many survivors and thrivers, he quickly discovered that information alone isn’t enough. What people often need most is connection — the chance to speak openly with others who truly understand the lived experience of cancer.

That realization became the foundation of AnCan.

Rick shares how traditional support models don’t always meet people where they are. Geographic limitations, physical health challenges, financial strain, rare diagnoses, and even the emotional weight of walking into an in-person group can all create barriers. For many, simply showing up can feel overwhelming.

AnCan was built to remove as many of those barriers as possible.

Rick’s full interview in Rarity Life offers an inspiring look at leadership shaped by lived experience, and a reminder that meaningful change often begins with one person asking: How can we do this better?

 

Read more stories & Rick’s article here:
https://www.samebutdifferentcic.org.uk/raritylife
2nd Opinions for MRIs

2nd Opinions for MRIs

by | Feb 25, 2026 | Active Surveillance PCa, Health Resources, High Risk/Recurrent/Advanced Prostate Cancer, Low/Intermediate Prostate Cancer, Prostate Cancer

Thank you to Eric Milsen for putting together this list of 2nd opinions for MRIs.

 

1. Botimage AI for MRIs
https://botimageai.com/prostatid/ ($250, can also be used for biopsy targeting guidance)

2. NIH 2nd Opinion MRI (no fees)
Choyke, Peter (NIH/NCI) Radiologist (pchoyke@mail.nih.gov)

3. Second opinion of MRI from Johns Hopkins
Images and Reports for Providers | Johns Hopkins Radiology (hopkinsmedicine.org)
Email: eradiologycenter@jhmi.edu
Phone: 443-287-7378
Fax: 443-769-1210

4. Accolade Radiology NY, PA
https://accoladeradiology.com/mritap.html

5. Radiology Check (Switzerland)
https://radiologycheck.com/en

 

 

AnCan GU ASCO26 survivorship poster: participants strongly endorse our Groups

AnCan GU ASCO26 survivorship poster: participants strongly endorse our Groups

by | Feb 23, 2026 | Active Surveillance PCa, Advocacy, Cancer Caregivers, Cancer Resources, Exercise, Low/Intermediate Prostate Cancer, mCRPC, Men 'Speaking Freely', Mental Health, mHSPC, Nutrition, Press, Prostate Cancer, Recent News, Uncategorized

AnCan | Virtual Support Calls

AnCan GU ASCO26 survivorship poster: participants strongly endorse our Groups

For release on Monday, Feb 23, 2026

AnCan Foundation strongly believes we run the best support groups available!! We can now release the first results of our 2024 AnCan Participant Survey that confirms that our participants think so too. This first batch of results is taken from almost 300 prostate cancer responses at all levels of disease.

  • 99% of respondents would recommend AnCan Groups
  • 66% improved Quality of Life – 83% noted reduced stress; 62% improved nutrition; 56% increased exercise
  • 88% advocated better for themselves and AnCan influenced over half (54%) the treatment paths
  • 47% made new friendships – AnCan’s personal favorite since this extends support well beyond our Groups

If you’re attending GU ASCO26 , please stop by our poster on Friday, Feb 27 to meet Dr. John Antonucci, discuss these astonishing results and the AnCan method, and pick up a flyer of the poster.

CONTACT

 

 

 

ABSTRACT

Evaluating the impact of virtual peer-led support groups on prostate cancer survivorship: the AnCan experience.

John Antonucci*, Boykin B. Jordan, Anita Oppong, Richard Davis

  • Abstract Number: 265
  • Poster Board Number: A23
  • Session Title: Poster Session B: Prostate Cancer and Urothelial Carcinoma
  • Date and Time: February 27, 2026, 11:30 AM-12:45 PM; 4:45 PM-5:45 PM (PST)

Background: Comprehensive prostate cancer (PCa) survivorship requires more than just clinical care, including education, psychosocial support, self-advocacy, and lifestyle guidance—needs often unmet by traditional oncology visits. Virtual peer-led support groups, such as those offered by the AnCan Foundation, offer accessible, real-time platforms for patients to share experiences, receive guidance, and foster community, regardless of geography. This study evaluates the impact of AnCan participation on factors known to be associated with a better quality of life (QOL) among PCa survivors.

Methods: A web-based survey was administered in 2024 to PCa survivors who attended or expressed interest in AnCan meetings. Respondents (N=294) provided demographic information and rated AnCan’s impact on QOL, peer support, self-advocacy, and satisfaction. Data were analyzed to assess the subjective influence of AnCan’s virtual support model on survivorship.

Results: (2021 results are in brackets for comparison.) Most respondents were in their 60s–70s (75%), highly educated (82%), and 55% had incomes over $100,000. Eighty-three percent had someone in their lives they could rely on and with whom they maintained regular contact.
Nearly all (97%) found AnCan meetings helpful for disease understanding, learning options, and well-being. Sixty-six percent reported improved QOL; 83% [50%] noted reduced stress; 62% [38%] improved nutrition; and 56% [58%] increased exercise. Satisfaction was high, with 99% recommending AnCan.

AnCan involvement enhanced self-advocacy (88%), improved patient-provider communication, and improved decision-making. Seventy percent brought information from AnCan to their providers, 49% added new providers, and 40% changed their lead provider. Over half (54%) reported that AnCan influenced their treatment path.

Socially, 55% [43%] connected with peers outside meetings, and 47% made new friendships.

Conclusions: Survey responses indicate that the AnCan virtual peer-led model, to be described in the poster, meaningfully increases patient knowledge, empowers self-advocacy, reduces stress, and fosters healthy behaviors, improving quality of life for PCa survivors. We advocate for integrating such peer support into NCCN, AUA, and ASCO survivorship guidelines.

POSTER